Imaging-based diagnostic systems for hepatocellular carcinoma

American Journal of Roentgenology

Volumn 201, Issue 1, 2013, Pages 41-55

  Cruite, Irene ^a   Tang, An ^b   Sirlin, Claude B ^c  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Imaging based diagnostic systems

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; EUROPE; HEPATOGRAPHY; HUMAN; JAPAN; LIVER CELL CARCINOMA; MEDICAL SOCIETY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; EUROPE; HUMANS; JAPAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84883413585     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.10570     Document Type: Review

References (54)

1. Taouli B, Krinsky GA. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006; 12(suppl 2):S1-S7
2. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology 2004; 47:191-198
3. Burrel M, Llovet JM, Avuso C, et al.; Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034-1042
4. Hanna RF, Kased N, Kwan SW, et al. Doublecontrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR 2008; 190:47-57
5. Bruix J, Sherman M, Llovet JM, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. J Hepatol 2001; 35:421-430
6. Ito K, Mitchell DG, Siegelman ES. Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 2002; 10:75-92
7. Brancatelli G, Federle MP, Ambrosinis R, et al. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 2007; 61:57-69
8. Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141:526-535
9. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12:1504-1511
10. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16:262-278
11. Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2000 Liver Int 2012; 32:1053-1063
12. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7:350-391
13. Parikh P, Malhotra H, Jelic S; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(suppl 2):ii27-ii28
14. Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52(suppl 3):iii1-iii8
15. Van Vlierberghe H, Borbath I, Delwaide J, Henrion J, Michielsen P, Verslype C; BASL HCC Working Group. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 2004; 67:14-25
16. Abdo AA, Karim HA, Al Fuhaid T, et al. Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Ann Saudi Med 2006; 26:261-265
17. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases, Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236
18. Park JW; Korean Liver Cancer Study Group and National Cancer Center. Practice guideline for diagnosis and treatment of hepatocellular carcinoma (in Korean). Korean J Hepatol 2004; 10:88-98
19. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4:439-474
20. Poon D, Anderson BO, Chen LT, et al.; Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2000 Lancet Oncol 2009; 10:1111-1118
21. Kim RD, Reed AI, Fujita S, Foley DP, Mekeel L, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg 2007; 205:108-123
22. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12:828-829
23. Addeo R, Caraglia M, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs 2009; 18:373-378
24. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation Guideline: hepatocellular carcinoma (HCC)-a global perspective. J Gastrointestin Liver Dis 2010; 19:311-317
25. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28:3994-4005
26. Organ Procurement and Transplantation Network. OPTN/UNOS policy 3.6.4. 4. Organ Procurement and Transplantation Network website. optn.transplant.hrsa. gov/PoliciesandBylaws2/ policies/pdfs/policy-8.pdf. Published December 13, 2012 Accessed January 8, 2013
27. American College of Radiology. Liver Imaging Reporting and Data System, version 2013. 1. American College of Radiology website. www. acr.org/Quality-Safety/Resources/LIRADS/. Published 2012 Accessed January 8, 2013
28. American College of Radiology. Liver Imaging Reporting and Data System, version 1. 0. American College of Radiology website. www.acr.org/Quality-Safety/ Resources/LIRADS/Archive/. Published 2012 Accessed January 8, 2013
29. Ito K, Fujita T, Shimizu A, et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR 2004; 183:699-705
30. Brancatelli G, Federle MP, Baron RL, Lagalla R, Midiri M, Vilgrain V. Arterially enhancing liver lesions: significance of sustained enhancement on hepatic venous and delayed phase with magnetic resonance imaging. J Comput Assist Tomogr 2007; 31:116-124
31. Ahn IO, de Lange EE. Early hyperenhancement of confluent hepatic fibrosis on dynamic MR imaging. AJR 1998; 171:901-902
32. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311-330
33. Kudo M, Izumi N, Kokudo N, et al.; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29:339-364
34. Japanese Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma (in Japanese). Japanese Society of Hepatology website. www.jsh. or.jp/. Published 2012 Accessed March 19, 2013
35. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38:37-51
36. Kokudo N, Sasaki Y, Nakayama T, Makuuchi M. Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians. Gut 2007; 56:1020-1021
37. Makuuchi M, Surname Intitial, Surname Intitial, et al. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma. Hepatol Res 2010; 40:6-7
38. Expert Panel of Japan Society of Hepatology. Clinical practice manual for hepatocellular carcinoma (in Japanese). Tokyo, Japan: Igaku-Shoin, 2007
39. Japan Society of Hepatology. Consensus-based clinical practice manual of hepatocellular carcinoma (in Japanese), 2nd ed. Tokyo, Japan: Igaku-Shoin, 2010
40. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943
41. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022
42. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010; 254:154-162
43. Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol 2008; 34:900-905
44. Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007; 52:3290-3295
45. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18:189-195
46. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244:898-906
47. Ahn SS, Kim MH, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255:459-466
48. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256:151-158
49. Lee S, Kim SH, Park CK, Kim YS, Lee WJ, Lim HK. Comparison between areas with Gd-EOBDTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation. J Magn Reson Imaging 2010; 32:719-725
50. Schneider G, Reimer P, Mamann A, Kirchin MA, Morana G, Grazioli L. Contrast agents in abdominal imaging: current and future directions. Top Magn Reson Imaging 2005; 16:107-124
51. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12:828-829
52. Abdo AA, Al Abdul Karim H, Al Fuhaid T, et al. Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Saudi J Gastroenterol 2007; 13:45-48
53. Jelic S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4):iv41-iv45
54. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943